LEPU ScienTech Reshuffles Company Secretary Roles, Retains Joint Structure for Governance

An announcement from LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H ( (HK:2291) ) is now available.

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. has announced a change in key corporate governance roles, with joint company secretary, process agent and authorised representative Mr. Li Kin Wai stepping down effective 30 December 2025 due to other work commitments, and Ms. Yeung Lai Shan being appointed to all three positions. The company also confirmed that the Hong Kong Stock Exchange has recognised deputy general manager and CFO Qin Xue as fully qualified to act as company secretary under the Listing Rules after the expiry of an earlier waiver; however, given the group’s Mainland China-focused operations and its aim to uphold strong corporate governance, LEPU ScienTech will retain a joint company secretary structure, with Hong Kong-based Ms. Yeung supporting Mr. Qin in fulfilling listing and compliance obligations, signalling continuity and stability for shareholders and regulators.

More about LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. is a PRC-incorporated medical technology group whose operations are principally based in Mainland China. The company is part of the broader Lepu ecosystem and focuses on medical technologies, supported by a corporate structure that includes a board of executive, non-executive and independent non-executive directors and an emphasis on maintaining high standards of corporate governance in both Mainland China and Hong Kong markets.

Average Trading Volume: 187,005

Technical Sentiment Signal: Sell

Current Market Cap: HK$5.7B

Find detailed analytics on 2291 stock on TipRanks’ Stock Analysis page.